FDA
-
-
-
-
-
-
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
-
-
-
-
-
-
Anaptys plans split into royalty and biopharma companies by 2026
-
-
-
-
-
-
-
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
-
-
-
-
-
-
-
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
-
-
-
-
-
-
-
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
-
-
-
-
-
-
-
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
-
-
-
-
-
-
-
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
-
325,892 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

